Nanosuspensions: The Solution to Deliver Hydrophobic Drugs
Keywords:
Nanosuspensions, Hydrophobic drugs, nanospheres, drug deliveryAbstract
Most of the drugs are not soluble in water and they create major problem during formulation they also show poor bioavailability. Reduction in particle size of such drugs enhances the dissolution rate and bioavailability. Nano suspension a promising delivery used to enhance the solubility of hydrophobic drugs. Media milling and high pressure homogenization technique are used commercially to produce nano suspensions. Recently emulsion and micro emulsion as templates are used to produce nano suspension. They are administered by Parenteral, per oral, ocular and pulmonary routes. Now their application also extended to site specific delivery. This review describes the methods of pharmaceutical nanosuspension production, formulations and pharmaceutical applications in drug delivery as well as the marketed products. Nanosuspensions consist of the pure poorly water-soluble drug without any matrix material suspended in dispersion.
References
. Lipinski C, Poor aqueous solubility- an industry wide problem in drug discovery, American Pharm Rev , 5,2002, 82-85.
. Elaine Merisko-Liversidge, Gary G. Liversidge, Eugene R.Cooper. Nanosizing: a formulation approach for poorly water-soluble compounds, Eur.J.Pharm.Sci, 11, 2003, 113-120.
. Guidance for industry waiver of In-Vivo Bioavailability and Bioequivalence studies for Immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. CDER, Aug. 2000.
. Nehal A.Kasim, Chandrasekharan Ramachndran, Marvial Bermejo,Hans Lennernas Ajaz S.Hussain,Hans E. Junginger, Saloman A.et.al. Molecular Properties of WHO Drugs and provisional Biopharmaceutical Classification. Molecular Pharmaceutics.
. Mitra.M, Christer.N, The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs, Int. J. Pharm,122, 1995, 35-47.
. Wong SM, Kellaway IW, Murdan S: Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 2006; 317:61-68.
. Parikh RK, Manusun SN, Gohel MC. And Soniwala MM: Dissolution enhancement of Nimesulide using complexation and salt formation techniques. Indian drugs. 2005; 42(3):149-154.
. Marazban S, Judith B, Xiaoxia C, Steve S, Robert OW, and Keith PJ: Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm, 2002; 243, . 17-31.
. True LR, Ian BG, James EH, Kevin LF, Clindy AC, Chritoper JT et.al: Development And characterization of a scalable controlled precipitation process to enhance the dissolution of poorly soluble drugs. Pharm Res, 2004; 21(11): 2048-2057.
. Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ: Applications of microemulsion based drug delivery system. Cur Dr Delivery, 2006; 3(3): 267-273.
. Riaz M: Stability and uses of liposomes. Pak Pharm Sci, 1995; 8(2): 69-79.
. Christian L and Jennifer D: Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 2000; 50(1): 47-60.
. Challa R, Ahuja A, Ali J, Khar R: Cyclodextrins in Drug Delivery: An Updated Review. AAPS PharmSciTech, 2005; 06(02): E329-E357.
. Kostas K, The emergence of Nanomedicine,1, 2006,1-3.
. Miglietta A. et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 2000; 210: 61–67
. Müller RH, Mäder, and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European J. Pharm. & Biopharm. 2000; 50: 161-177.
. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc Chem Res 2000; 33: 94-101.
. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEG-ylated systems. Pharmazie 2002; 57: 5-29.
. Cavalli R, Peira E, Caputo O, and Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrin. Int. J. Pharm. 1999; 59-69.
. Jenning V., Lippacher, A., and Gohla, S. H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenisation. J Microencap. 2002;19:1-10.
. Shobha R, Hiremath R and Hota A: Nanoparticles as drug delivery systems. Ind J Pharm Sci, 1999; 61(2): 69-75.
. Barret ER: Nanosuspensions in drug delivery. Nat rev, 2004 ;( 3): 785-796.
. R H Muller, Gohla S, Dingler A, Schneppe T: Large-scale production of solid-lipid nanoparticles (SLN) and nanosuspension (Dissocubes). In D.Wise (Ed.) Handbook of pharmaceutical controlled release technology, 2000; 359-375.
. Liversidge GG, Cundy KC.Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oralbioavailability of nanocrystalline danazol in beagle dogs.Int J Pharm. 1995; 125(1): 91 97.doi:10.1016/0378-5173(95)00122-Y
. RH Muller, C Jacobs and O Kayer. Nanosuspensions for the formulation of poorly soluble drugs. In: F Nielloud, G Marti- Mestres (ed). Pharmaceutical emulsion and suspension. New York, Marcel Dekker, 2000, p. 383-407.
. GG Liversidge and P Conzentino. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995; 125, 309-13.
. Michele T, Marina G, Maria EC and Silvia M: Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int J Pharm, 2003; 254, 235-42.
. Tejal S, Dharmesh P, Jayshukh H and Avani FA: Nanosuspensions as a drug delivery system: A comprehensive review. Drug Deliv Tech, 2007; 7, 42-53
. Gary GL, Phil C: Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 1995; 125, 309-13.
. un-ichi J, Naoki K, Masateru M, Keigo Y, Tadashi M, Masaaki O et.al: Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111, 56-64.
. Wongmekiat A, Tozuka Y, Oguchi T and Yamamoto K: Formation of fine drug particles by co-grinding with cyclodextrin. I. the use of β-cyclodextrin anhydrate and hydrate. Pharm Res, 2002; 19, 1867-72.
. Jacobs C, Kayser O and Müller RH: Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm, 2001; 214, 3-7.
. Sugimoto M, Okagaki T, Narisawa S, Koida Y and Nakajima K: Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel co-grinding method using water soluble polymer. Int J Pharm, 1998; 160, 11-9.
. Etsuo Y, Shinichi K, Shuei M, Shigeo Y, Toshio O, Keiji Y: Physicochemical properties of amorphous clarithromycin obtained by grinding andspray drying. Eur J Pharm Sci, 1999; 7, 331-8.
. Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K: Nanoparticle formation of poorly water soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull, 2003; 51, 171-4.
. Müller RH and Jacobs C: Buparvaquone mucoadhesive nanosuspension: preparation, optimization and long-term stability. Int J Pharm, 2002; 237, 151-61.
. Moschwitzer J, Achleitner G, Promper H, Muller RH: Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm, 2004; 58, 615-9.
. Grau, M. J., Kayser, O., Mu¨ ller, R. H. (2000) Nanosuspensions of poorly soluble drugs – reproducibility of small-scale production. Int. J. Pharm. 196: 155–157.
. Mu¨ ller, R. H., Bo¨ hm, B. H. L. (1998) Nanosuspensions. In: Mu¨ ller, R. H., Benita, S., Bo¨ hm, B. H. L. (eds) Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm Scientific Publishers, Stuttgart, pp 149–174.
. Bodmeier, R.; McGinity, J.M. Solvent selection in the preparation of poly(DLlactide) microspheres prepared by solvent evaporation method. Int. J.Pharm., 1998, 43, 179-186.
. VB Patravale, AA Date and RM Kulkarni. Nanosuspension: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004; 56, 827 40.
. M Trotta, M Gallarate, ME Carlotti and S Morel. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int. J. Pharm. 2003; 254, 235-42.
. Marazban S, Judith B, Xiaoxia C, Steve S, Robert OW, and Keith PJ: Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm, 2002; 243, 17-31.
. Xiaoxia C, Timothy JY, Marazban S, Robert OW and Keith PJ: Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm, 2002; 242, 3-14.
. Zohra Z, Souad S, Hatem F: Preparation and characterization of poly-εcarprolactone nanoparticles containing griseofulvin. Int J Pharm, 2005; 294,261-7.
. Bodmeier, R., McGinity, J. M. (1998) Solvent selection in the,preparation of poly (DL-lactide) microspheres prepared by solvent evaporation method. Int. J. Pharm. 43: 179–186.
. Trotta, M., Gallarate, M., Pattarino, F., Morel, S. (2001) Emulsions containing partially water miscible solvents for the preparation of drug nanosuspensions. J. Control. Release 76: 119–128.
. Eccleston, G. M. (1992) Microemulsions. In: Swarbrick, S., Boylan, J. C. (eds) Encyclopedia of pharmaceutical technology. Vol. 9, Marcel Dekker, New York, pp 375–421.
. Constantinides, P. P., Scarlart, J. P., Smith, P. L. (1994) Formulation and intestinal absorption enhancement evaluation of water in oil microemulsions incorporating mediumchain triglycerides. Pharm. Res. 11: 1385–1390.
. Kim, C. K., Hwang, Y. Y., Chang, J. Y., Choi, H. G., Lim, S. J., Lee, M. K. (2001) Development of a novel dosage form for intramuscular injection of titrated extract of Centella asiatica in a mixed micellar system. Int. J. Pharm. 220: 141–147.
. Park, K., Kim, C. K. (1999) Preparation and evaluation of flurbiprofen-loaded microemulsion for parenteral delivery. Int. J. Pharm. 181: 173–179.
. Kawakami, K., Yoshikawa, T. (2002) Microemulsion formulation for enhanced absorption of poorly soluble drugs I. Prescription design. J. Control. Release 81: 65–74.
. Gasco, M. R. (1997) Solid lipid nanospheres form warm microemulsions. Pharm. Technol. Eur. 9: 32–42.
. Rades, T., Davies N., Watnasirichaikul, S., Tucker, I. (2002) Effects of formulation variables on characteristics of poly (ethylcyanoacrylates) nanocapsules prepared from w/o microemulsions. Int. J. Pharm. 235: 237–246.
. She ZY, Ke X, Ping QN, Xu BH and Chen LL: Preparation of breviscapine
. nanosuspension and its pharmacokinetic behavior in rats. Chin J Nat Med, 2007; 5, 50-5.
. Rawlins, E. A. (1982) Solutions. In: Rawlins, E. A. (ed.) Bentley’s textbook of pharmaceutics. 8th edn, Bailliere Tindall, London, p 6.
. Dressman, J. B., Amidon, G. L., Reppas, C., Shah, V. P. (1998) Dissolution testing as a prognostic tool for oral drug adsorption: immediate release dosage forms. Pharm. Res. 15: 11–22.
. Peters, K., Mu¨ ller, R. H., Borner, K., Hahn, H., Leitz, K. S., Diederichs, J. E., Ehlers, S. (2000) Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45: 77–83.
. Chen, Y.; Liu, J.; Yang, X.; Zhao, X.; Xu, H. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect. J. Pharm. Pharmacol., 2005, 57, 259-264.
. Setler P. Identifying new oral technologiesmto meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. IIR Limited, Drug delivery systems London: 1999.
. Liversidge GC. Paper presented at the 23 rd International symposium of the Society. Workshop on Particulate Drug Controlled Release Bioactive Materials Delivery Systems; 1996.
. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A. F., Croft, S. L. (2003) Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254: 73–75.
. Liversidge, G. G., Conzentino, P. (1995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125: 309–313.
. R Pignatello, C Bucolo, P Ferrara, A Maltese, A Pvleo and G Puglisi. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 2002; 16, 53-61.
. MA Kassem, AA Abdel Rahman, MM Ghorab, MB Ahmed and RM Khalil. Nanosuspension as an opthamic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 2007; 340, 126-33.
. RH Müller and C Jacobs. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002; 19, 189-94.
. N Hernández-Trejo, O Kayser, H Steckel and RH Müller. Characterization of nebulized bupravaquone nanosuspensions-Effect of nebulization technology. J. Drug. Target. 2005; 13, 499-507.
. E Merisko-Liversidge, GG Liversidge and ER Cooper. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003; 18,113-20.
. O Kayser. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. Int. J. Pharm. 2000; 196, 253-6
. B Rainbow, J Kipp, P Papadopoulos, J Wong, J Glosson, J Gass, C-S Sun, T Wielgos, R White, C Cook, K Barker and K Wood. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetic in the rat. Int. J. Pharm. 2007; 339, 251-60.
. O Kayser. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. J. Pharm. 2001; 214, 83-5.
. J Shim, HS Kang, W-S Park, S-H Han, J Kim and I-S Chang. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J. Control Rel. 2004; 97, 477-84.
. AK Kohli and HO Alpar. Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int. J. Pharm. 2004; 275, 13-7.
